CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 69 enrolled
Drug / intervention
Teriparatide +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01753856
NCT01753856Phase 4Completed
CompareCT.gov

Anabolism Versus Antiresorption: A Quadruple Labeling Histomorphometry Study to Compare the Mechanism of Action of Teriparatide and Denosumab in Postmenopausal Women With Osteoporosis

Eli Lilly and Company·interventional·Posted Dec 20, 2012·Updated Oct 8, 2015

In Brief

A Phase 4 clinical trial evaluating Teriparatide, Denosumab, and 4 other interventions for Osteoporosis. Completed, enrolled 69 participants across 6 sites in 2 countries.

Detailed Summary

The purpose of this study is to determine how teriparatide or denosumab affects the bone of postmenopausal women with osteoporosis after 3 months of treatment, as determined by a bone biopsy sample taken from the iliac crest (upper part of the pelvis).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesCanada, United States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 20, 2012
Enrollment StartJan 1, 2013
Primary CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 13.5 years ago

Interventions

Teriparatidedrug

Administered SC

Denosumabdrug

Administered SC

Demeclocyclinedrug

Administered orally

Tetracyclinedrug

Administered orally

Calcium Supplementdrug

Administered orally

Vitamin Ddrug

Administered orally